Prognostic relevance of CCAs/Ph− in CML settled: comment on Issa et al, page 2084
In this issue of "Blood", Issa et al. report that patients with chronic-phase chronic myeloid leukemia (CML) in remission after treatment with tyrosine kinase inhibitors (TKIs) with clonal chromosomal aberrations (CCAs) in Philadelphia chromosome-negative (Ph−) metaphases had a significant...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 9, 2017
|
| In: |
Blood
Year: 2017, Jahrgang: 130, Heft: 19, Pages: 2046-2047 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2017-09-804054 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1182/blood-2017-09-804054 Verlag, kostenfrei, Volltext: http://www.bloodjournal.org/content/130/19/2046 
|
| Verfasserangaben: | Rüdiger Hehlmann |
| Zusammenfassung: | In this issue of "Blood", Issa et al. report that patients with chronic-phase chronic myeloid leukemia (CML) in remission after treatment with tyrosine kinase inhibitors (TKIs) with clonal chromosomal aberrations (CCAs) in Philadelphia chromosome-negative (Ph−) metaphases had a significantly worse survival than similar patients without CCAs. This study is notable for the large number of patients with CCAs (n=58) and the length of follow up (median, 7.6 years) (see figure). |
|---|---|
| Beschreibung: | Gesehen am 09.04.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2017-09-804054 |